News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UK's National Institute for Clinical Excellence (NICE) Gives Rebuff To GlaxoSmithKline (GSK)'s Tykerb, Roche (RHHBY)'s Herceptin for Breast Cancer



12/15/2010 7:39:22 AM

Press Association -- Two drugs to treat breast cancer have been rejected for use on the NHS when combined with other therapies, according to new guidance. The National Institute for Health and Clinical Excellence (Nice) turned down Tyverb (lapatinib) and Herceptin (trastuzumab) when used in combination with an aromatase inhibitor (another type of breast cancer treatment).

Read at Wall Street Journal
Read at News Release
Read at Reuters
Read at Press Assoc. (PA)


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES